<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145066</url>
  </required_header>
  <id_info>
    <org_study_id>not yet assigned</org_study_id>
    <secondary_id>P50 AT 0027820</secondary_id>
    <nct_id>NCT01145066</nct_id>
  </id_info>
  <brief_title>Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects</brief_title>
  <official_title>Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare how well a combination of borage and echium oils will reduce
      inflammation compared to fish oils and placebo oil in subjects that are diabetic or have
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>leptin</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>leptin</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>leptin</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum fatty acids</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro and anti-inflammatory cytokines</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin 1Ac</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose derived cytokines</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating blood lipids and blood cell components</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC gene expression</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNPs in DNA of selected genes</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC leukotriene stimulation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum fatty acids</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum fatty acids</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro and anti-inflammatory cytokines</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro and anti-inflammatory cytokines</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin 1Ac</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin 1Ac</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose derived cytokines</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose derived cytokines</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating blood lipids and blood cell components</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating blood lipids and blood cell components</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC gene expression</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC gene expression</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNPs in DNA of selected genes</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNPs in DNA of selected genes</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC leukotriene stimulation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC leukotriene stimulation</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes</condition>
  <condition>Metabolic Syndrome x</condition>
  <arm_group>
    <arm_group_label>borage and echium oil combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Croda 18:12 fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corn oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>borage/echium oil combination</intervention_name>
    <description>borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA</description>
    <arm_group_label>borage and echium oil combination</arm_group_label>
    <other_name>Croda echium oil SR06379</other_name>
    <other_name>Croda borage oil, Crossential GLA TG40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil</intervention_name>
    <description>1.6g/day EPA and 1.08g/day DHA</description>
    <arm_group_label>fish oil</arm_group_label>
    <other_name>Croda 18:12 fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>corn oil</intervention_name>
    <description>contains 4.5 g/day linoleic acid</description>
    <arm_group_label>corn oil</arm_group_label>
    <other_name>Croda superrefined corn NF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults, aged 21 years or more with either diabetes or metabolic syndrome. metabolic
             syndrome defined by NCEP/ATPIII criteria; must have 3 out of 5 of the following risk
             factors: 1.central obesity, men-greater than or equal to 40 inches, women-greater than
             or equal to 35 inches; 2.fasting blood TG greater than or equal to 150mg/dl or be
             taking TG lowering medications; 3. blood HDL cholesterol, men less than 40 mg/dl,
             women less than 50 mg/dl; 4. blood pressure greater than or equal to 130/85 or on HTN
             medication 5. fasting glucose greater than or equal to 100 mg/dl.

          -  participants on statins or glucose lowering drugs if dosages are stable for 3 months

        Exclusion criteria

          -  children/young adults less than 21 years of age

          -  currently using anti-inflammatory drugs including NSAIDS, oral/IV steroids or
             injection antiinflammatory drugs(for RA), aspirin greater than 100mg/day

          -  taking leukotriene receptor antagonists ( montelukast), tylenol or nasal/inhaled
             steroids OK.

          -  currently using niacin, fibrates or fish oil

          -  blood pressure greater than 170/100

          -  HB1Ac greater than 10%

          -  TG greater than 500 mg/dl

          -  myocardial infarction/vascular surgery/stroke within the past year

          -  any stage II,III,IV heart failure

          -  prior cholecystectomy

          -  end stage renal disease

          -  BMI less than 23 or greater than 45

          -  pregnancy

          -  alcohol use greater than 14 drinks per week

          -  current self reported tobacco or illicit drug use

          -  intolerance or allergy to fish oil

          -  participants taking insulin on QD or BID doses, stable for 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Floyd(Ski) H Chilton, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>inflammation</keyword>
  <keyword>botanical oils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

